As of 3:59pm ET
| +0.0023 / +0.58%|
The 2 analysts offering 12-month price forecasts for ImmunoCellular Therapeutics Ltd have a median target of 42.50, with a high estimate of 80.00 and a low estimate of 5.00. The median estimate represents a +10,525.00% increase from the last price of 0.40.
The current consensus among 1 polled investment analysts is to Hold stock in ImmunoCellular Therapeutics Ltd. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.